Ex Vivo

refers to biological studies involving tissues, organs, or cells maintained outside their native organism under controlled laboratory conditions. By carefully managing factors such as temperature, oxygenation, nutrient delivery, and perfusing a nutrient solution through the tissue's vasculature, researchers sustain function long enough to conduct experiments that would be difficult or unethical in a living body. ''Exvivo'' models occupy a middle ground between '' in vitro'' () models, which typically use isolated cells, and '' in vivo'' () studies conducted inside living organisms, offering both experimental control and physiological relevance.

''Ex vivo'' platforms support pharmacologic screening, toxicology testing, transplant evaluation, developmental biology, and investigations of disease-mechanism research across medicine and biology, from cardiology and neuroscience to dermatology and orthopedics. Because they often use human tissues obtained from clinical procedures or biobanks, they can reduce reliance on live-animal experimentation; their utility, however, is limited by finite viability, incomplete systemic integration, and post-mortem biochemical changes that accumulate over time. The earliest perfusion studies were conducted in the mid-19thcentury, and subsequent advances in sterilization, imaging, and microfluidics have facilitated broader adoption into the 20th and 21stcenturies. Regulatory oversight depends on specimen origin: human ''exvivo'' research is subject to informed consent, whereas animal-derived models fall under institutional animal care guidelines.

Principles and definition

''Ex vivo'', literally 'out of the living' in Latin, refers to biological studies involving tissues, organs, or cells maintained outside their native organism under tightly controlled laboratory conditions. These studies preserve the extracted materials' viability and structural integrity for limited periods by managing conditions such as oxygenation, temperature, nutrient delivery, and humidity, depending on the specific requirements of the model. These conditions are often facilitated through cell culture media or specialized perfusion chambers. As an intermediate approach between '' in vitro'' studies—which typically use isolated cells in artificial environments—and '' in vivo'' research conducted within living organisms, ''exvivo'' models preserve more of the native tissue architecture than traditional cell cultures, while offering greater experimental control than whole-organism studies. In doing so, ''exvivo'' models address some of the limitations of ''invitro'' work, such as oversimplified cellular interactions, and help mitigate the systemic variability and complexity inherent to ''invivo'' models.

In the preclinical development of therapies for bone diseases, for example, ''in vitro'' cell studies are typically performed prior to ''in vivo'' testing in animal models, as the latter approach is more costly, time-intensive, and complex, requiring large sample sizes to yield statistically meaningful results. However, ''in vitro'' findings frequently fail to predict ''in vivo'' responses due to the absence of native tissue architecture, including the extracellular matrix (ECM), and the lack of physiologically relevant cell–cell as well as cell–matrix interactions. ''Ex vivo'' bone explant cultures preserve these features by maintaining tissue integrity outside the organism, and reduce the complexity of ''in vivo'' testing by excluding systemic variables, enabling controlled investigation of specific biological or mechanical factors.

Another example is the use of ''ex vivo'' models during the preclinical evaluation of intestinal drug transport. Unlike ''in vivo'' studies, which rely on animal models and are affected by interspecies differences, ''ex vivo'' approaches can utilize resected human intestinal segments, more accurately representing human physiological conditions.

The boundary between ''exvivo'' and ''invitro'' models remains contested, particularly in the fields of regenerative medicine and tissue engineering, where the terms have been used interchangeably in many studies. Modern ''invitro'' systems have progressed from simple two-dimensional cell cultures to advanced three-dimensional constructs, such as organoids and organ-on-a-chip devices, that replicate aspects of tissue architecture, further complicating the distinction. Klein and Hutmacher (2024) propose that a model may be classified as ''exvivo'' if it meets one or more of the following criteria: it preserves the native structure and composition of a cell, tissue, or organ without disrupting its cellular or extracellular components; it is used in therapeutic contexts where cells, organs, or tissues are removed and then reimplanted; or it links explanted organs or tissues to artificial circulation via perfusion. According to these criteria, systems involving extensive reorganization or manipulation—including organoids, organ-on-a-chip, and organotypic cultures—are considered ''invitro'', even when they replicate certain organ-level functions.

In general, ''invitro'' models are highly flexible and relatively inexpensive, making it easier to test new treatments quickly and adjust experimental parameters as needed. ''Exvivo'' systems are less adaptable but often provide a more reliable indication of how a treatment will work, and what side effects it might cause, in the human body. Nonetheless, they are subject to inherent limitations, including post-mortem alterations in biophysical properties, progressive tissue degradation, limited viability duration, and, typically, the absence or artificial replication of circulation and innervation. These constraints can hinder the models' ability to reproduce long-term or systemic physiological effects. Some of these factors complicate direct comparisons with ''invivo'' systems; for example, studies measuring how electric fields behave in primate brain tissue during stimulation have found that results differ markedly between ''in vivo'' and ''ex vivo'' conditions—and the longer the tissue has been removed from the body, the greater the discrepancy, partly due to cooling and loss of normal biological function.

Techniques and applications

Organ perfusion

Organ perfusion involves circulating oxygenated solutions through isolated organs to sustain their viability. For example, ex vivo lung perfusion (EVLP) is used to evaluate donor lungs prior to transplantation. An system includes a ventilator connected to the lung via an endotracheal tube to simulate natural respiration and enable alveolar gas exchange. The typical perfusion circuit consists of a centrifugal pump to circulate the perfusate, a reservoir to collect effluent, a heat exchanger for temperature regulation, a leukocyte filter to remove white blood cells, a flow probe to measure perfusate flow, and a membrane gas exchanger to adjust oxygen and carbon dioxide concentrations in the circulating fluid. Cannulas link the circuit to the lung's pulmonary artery and left atrial cuff.

In cardiovascular research, a Langendorff heart preparation removes a heart and perfuses it with a nutrient solution, preserving structure and conduction pathways for investigation of arrhythmias or drug effects without the complexity of an '' in vivo'' model. Several ''ex vivo'' perfusion systems have been developed to reduce ischemic injury during the organ preservation phase. One such system is the Organ Care System (OCS), which maintains the heart in a non-beating but metabolically active state by circulating heparinized donor blood supplemented with a proprietary perfusate formulation. In translational pharmacology, perfusion platforms restore pulsatile blood flow in isolated human organs, enabling direct measurement of absorption, metabolism, and toxicity prior to first-in-human trials. By supplying pharmacokinetic data on viable human tissue rather than relying on animal models or cell assays, the platforms inform clinical trial decisions and may reduce animal testing.

Not all forms of organ perfusion are ''ex vivo''; '' in situ'' perfusion techniques are employed during organ retrieval to restore blood flow to organs while they remain within the body, minimizing ischemic injury and preserving viability for transplantation. A related example is selective ''insitu'' perfusion during surgery, such as isolated hepatic perfusion (IHP), which is used for targeted chemotherapy.

Organ culture

Organ culture typically involves maintaining organ sections or small fragments in static or semi-static conditions without active perfusion. The use of culture media to sustain excised tissues or organs does not alter their classification as ''ex vivo'' models, provided that the native tissue architecture remains preserved, in accordance with the criteria proposed by Klein and Hutmacher (2024). In dermatological research, human skin organ culture (HSOC) is a technique in which excised human skin is maintained in an artificial medium that preserves its native architecture. models are employed to study wound healing, drug penetration, and toxicological responses. By retaining the structural complexity of human skin, these models facilitate the investigation of conditions that are not reproducible in animal models, such as keloid formation.

Cell culture involves isolating individual cells from tissues and growing them in a medium enriched with nutrients and growth factors. While these cultures retain some functional characteristics of their tissue of origin, they often exhibit changes in phenotype and gene expression when removed from their native environment. Primary cell cultures, derived directly from tissues, more closely resemble physiological conditions than immortalized cell lines, making them essential for studying cellular behavior, disease mechanisms, and drug effects.

Microscopy and imaging

''Ex vivo'' microscopy (EVM) uses advanced digital microscopes—such as confocal or optical-coherence devices—to produce microscopic images of fresh tissue, without mounting thin sections on glass slides. Because the tissue stays intact, surgeons can assess tumor margins or examine biopsy samples during surgery.

Computed tomography (CT) is used in ''ex vivo'' research to produce non-destructive, high-resolution images of internal structures.

Energy–tissue interaction studies

Human skin explants from surgical procedures allow researchers to observe early-stage physiological responses to laser treatments in ways that closely resemble ''invivo'' conditions, though processes like re-epithelialization occur more slowly than in living tissue. In intervertebral disc research, ''ex vivo'' models that retain vertebral bone allow for testing potential drugs and investigating loading effects on disc degeneration and repair.

In biosensing and electroanalytical applications, ''ex vivo'' methods offer experimental flexibility unavailable in living systems. While many ''in vivo'' experiments favor micro- and nanoelectrodes to minimize invasiveness, larger electrodes are routinely used for specific purposes. ''Exvivo'' approaches, by contrast, permit custom electrode geometries that interface precisely with biological tissues under controlled conditions, without the same constraints on size and invasiveness. This adaptability enables detailed examination of biological analytes and their physiological roles. ''Exvivo'' electroanalytical methods are applied in neuroscience, pharmacology, and biomedical engineering to study neurotransmitter dynamics, metabolic activity, and disease-associated biomarkers.

In some cases, ''ex vivo'' electroporation, in which an electric field is applied to cells to facilitate the uptake of genetic material, is used to introduce DNA into cells within tissue slices, allowing researchers to study gene expression in a controlled environment.

History

The foundations of ''exvivo'' experimentation were laid in the 19th century. In 1846, German physiologist Carl Ludwig and his student Carl Wild conducted one of the earliest perfusion studies, connecting the heart of a deceased animal to the common carotid artery of a living donor animal. This configuration allowed the donor's circulation to perfuse the coronary vessels of the excised heart. However, because the heart's viability remained dependent on a living organism rather than an artificial perfusion system, the preparation does not meet the strict criteria for ''ex vivo'' experimentation. The earliest known studies involving the perfusion of kidneys outside the native organism were conducted by German physiologist Carl Eduard Loebell, who presented his findings in a doctoral dissertation in 1849. In 1866, Russian physiologist Elias von Cyon developed the isolated perfused frog heart preparation at the Carl Ludwig Institute of Physiology in Leipzig, Germany. This method was commonly used during the late 19thcentury and later served as the basis for the isolated perfused mammalian heart preparation. In 1876, German physiologist Gustav von Bunge and German pharmacologist Oswald Schmiedeberg demonstrated the synthesis of hippuric acid in the isolated dog kidney. In 1885, German physiologist Maximilian von Frey and Austrian biologist Max von Gruber, working at the Carl Ludwig Institute of Physiology, constructed an apparatus combining a mechanical pump with an early oxygenator that substituted the function of the heart and lungs in experiments on dogs. This device oxygenated blood outside the body and was a precursor to the heart–lung machine.

In the 1880s, British physiologist Sydney Ringer developed a salt solution that sustained rhythmic contractions in the isolated frog heart. Later named Ringer's solution, it enabled extended observation of cardiac activity and supported controlled experimental studies on cardiac physiology in isolated preparations. In 1895, German physiologist Oskar Langendorff introduced a method for isolated heart perfusion involving retrograde flow through the aorta to supply the coronary circulation. The Langendorff preparation allowed for direct measurement of cardiac function and precise control of perfusion parameters while minimizing systemic confounders inherent to '' in vivo'' models. It became a widely used technique in the study of cardiac physiology and remains a standard method in cardiovascular research. At the turn of the 20thcentury, researchers initiated efforts to preserve animal tissues ''exvivo'' within laboratory settings. Early experiments involved isolating tissues from organisms and transferring them to external media to develop reliable cultivation techniques. These studies aimed not only to maintain cellular viability but also to stimulate tissue growth, often using blood plasma—typically sourced from the same animal—as the medium.

In 1935, French surgeon Alexis Carrel and American aviator Charles Lindbergh unveiled the first closed, sterile perfusion pump. The glass-enclosed, three-chamber device maintained a pulsatile flow of oxygenated perfusate through explanted animal thyroid glands, keeping them viable for up to three weeks '' in vitro''. Their fragments were then transferred to culture flasks, where they gave rise to proliferating cell colonies, verifying ''exvivo'' viability. By equalizing pressure and continuously recirculating the medium, the apparatus proved that long-term organ maintenance outside the body was feasible and laid the groundwork for modern perfusion culture techniques. In 1953, American surgeon John Heysham Gibbon successfully employed a heart–lung machine during open-heart surgery on a human patient. The procedure demonstrated that an artificial circuit with controlled oxygenation and temperature could temporarily maintain systemic circulation. Throughout the 20thcentury, ''exvivo'' techniques were adapted for a range of animal models. A notable refinement was the development of the working heart model, in which perfusate enters the left atrium and exits through the aorta, more closely replicating physiological flow conditions. Advances in instrumentation enabled detailed assessments of cardiac function, including pressure–volume relationships, oxygen consumption, and myocardial contractility.
The artificial organ field contributed significantly to the advancement of ''exvivo'' systems; for example, the development of hemodialysis relied on a series of ''exvivo'' models designed to support and test extracorporeal circulation technologies.

Ethical and legal aspects

Some ''exvivo'' models may offer ethical benefits by reducing reliance on live-animal experimentation relative to ''in vivo'' approaches, enabling researchers to conduct physiologically relevant studies without using whole, living organisms. In certain cases, animals already intended for slaughter may be used as tissue sources. The Langendorff heart preparation requires the use of live animals, as it involves the excision and immediate perfusion of the heart to preserve viability for experimental analysis; however, adaptations of the technique can reduce the number of animals needed for certain protocols by enabling multiple experimental applications from a single specimen.

Human tissues for ''exvivo'' models are typically obtained from clinical procedures, such as surgical discards, donations, biopsies, or through accredited biobanks. Tissues obtained shortly after death through autopsy are used in some cases, particularly for studies focused on maintaining structural integrity or assessing short-term functional properties. Although human tissues provide the highest degree of physiological relevance, their use is subject to inter-sample heterogeneity (e.g., age, gender, medication history, and diet), logistical challenges in obtaining region-specific samples, and ethical constraints. In many jurisdictions worldwide, the acquisition and research use of human tissues are regulated by ethical and legal frameworks that require informed consent. In Japan, the , implemented in 2021, consolidate previous standards and mandate that researchers obtain informed consent when conducting studies involving human tissues. In Switzerland, the Federal Act on Research involving Human Beings (Human Research Act, HRA) stipulates that all research involving identifiable human tissue must be approved by an ethics committee. Researchers are required to obtain written informed consent from donors, and documentation concerning the origin of the tissue and the consent procedure must be submitted as part of the ethical review process.

In the United Kingdom, the legal framework governing the removal, storage, and use of human tissue for research varies by jurisdiction. In England, Wales, and Northern Ireland, the Human Tissue Act 2004 mandates that appropriate consent must be obtained for the removal and use of tissue from both the living and the deceased, unless specific statutory exemptions apply. The Act includes provisions introduced in response to public health scandals in the 1990s, such as the Alder Hey and Bristol Royal Infirmary cases, in which thousands of children's organs were retained without parental knowledge. In Scotland, the Human Tissue (Scotland) Act 2006 regulates the removal, retention, and use of human tissue for purposes including transplantation and research. Unlike the 2004 Act, which relies on "appropriate consent", the Scottish legislation is based on the principle of "authorisation" as the legal basis for the use of human tissue. The 2006 Act was subsequently amended by the Human Tissue (Authorisation) (Scotland) Act 2019, which introduced a system of deemed authorisation for organ and tissue donation after death. In Wales, the Human Transplantation (Wales) Act 2013 further diverged by introducing a system of deemed consent for post-mortem organ and tissue donation.

In the United States, federal regulations such as the Common Rule and those enforced by the Food and Drug Administration (FDA) stipulate that researchers must obtain informed consent when conducting studies involving human subjects, including the use of identifiable biological materials. The Health Insurance Portability and Accountability Act (HIPAA) further safeguards the confidentiality of personal health information, including data derived from tissue samples.

See also

* List of medical roots, suffixes and prefixes
*

Notes

References

Primary sources

{{DEFAULTSORT:Ex Vivo

Latin biological phrases
Latin medical words and phrases
Animal test conditions